[代谢功能障碍相关脂肪性肝病新药的临床现状与挑战]
[Clinical status and challenges of new drugs for metabolic dysfunction-associated fatty liver disease].
作者信息
Luo X, Lu L G, Mao Y M
机构信息
Department of Gastroenterology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China.
Department of Gastroenterology, Shanghai Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200001, China.
出版信息
Zhonghua Gan Zang Bing Za Zhi. 2024 Apr 20;32(4):300-302. doi: 10.3760/cma.j.cn501113-20240226-00096.
Metabolic dysfunction-associated fatty liver disease (MASLD) is a major public health problem that seriously affects human health. At present, some good progress has been made in the research and development of new drugs for MASLD, but there is still great space for exploration. This paper summarizes and analyzes the reasons in the current clinical status and challenges for the research and development of new drugs for MASLD.
代谢功能障碍相关脂肪性肝病（MASLD）是一个严重影响人类健康的重大公共卫生问题。目前，MASLD新药研发已取得一些良好进展，但仍有很大的探索空间。本文总结并分析了当前MASLD新药研发的临床现状及面临的挑战。
Zotero 插件